Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ribosome dysfunction underlies SLFN14-related thrombocytopenia

Fabienne Ver Donck, Kato Ramaekers, Chantal Thys, Christine Van Laer, Kathelijne Peerlinck, Chris Van Geet, Koji Eto, Veerle Labarque, Kathleen Freson

Blood (2023) 141 (18): 2261–2274.

https://doi.org/10.1182/blood.2022017712

Published: 2023

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Blood (2021) 138 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2021-146021

Published: 2021

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia

Blood (2017) 129 (4): 520–524.

https://doi.org/10.1182/blood-2016-08-732248

Published: 2017

Includes: Supplemental data

Journal Articles

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders

Ilenia Simeoni, Jonathan C. Stephens, Fengyuan Hu, Sri V. V. Deevi, Karyn Megy, Tadbir K. Bariana, Claire Lentaigne, Sol Schulman, Suthesh Sivapalaratnam, Minka J. A. Vries, Sarah K. Westbury, Daniel Greene, Sofia Papadia, Marie-Christine Alessi, Antony P. Attwood, Matthias Ballmaier, Gareth Baynam, Emilse Bermejo, Marta Bertoli, Paul F. Bray, Loredana Bury, Marco Cattaneo, Peter Collins, Louise C. Daugherty, Rémi Favier, Deborah L. French, Bruce Furie, Michael Gattens, Manuela Germeshausen, Cedric Ghevaert, Anne C. Goodeve, Jose A. Guerrero, Daniel J. Hampshire, Daniel P. Hart, Johan W. M. Heemskerk, Yvonne M. C. Henskens, Marian Hill, Nancy Hogg, Jennifer D. Jolley, Walter H. Kahr, Anne M. Kelly, Ron Kerr, Myrto Kostadima, Shinji Kunishima, Michele P. Lambert, Ri Liesner, José A. López, Rutendo P. Mapeta, Mary Mathias, Carolyn M. Millar, Amit Nathwani, Marguerite Neerman-Arbez, Alan T. Nurden, Paquita Nurden, Maha Othman, Kathelijne Peerlinck, David J. Perry, Pawan Poudel, Pieter Reitsma, Matthew T. Rondina, Peter A. Smethurst, William Stevenson, Artur Szkotak, Salih Tuna, Christel van Geet, Deborah Whitehorn, David A. Wilcox, Bin Zhang, Shoshana Revel-Vilk, Paolo Gresele, Daniel B. Bellissimo, Christopher J. Penkett, Michael A. Laffan, Andrew D. Mumford, Augusto Rendon, Keith Gomez, Kathleen Freson, Willem H. Ouwehand, Ernest Turro

Blood (2016) 127 (23): 2791–2803.

https://doi.org/10.1182/blood-2015-12-688267

Published: 2016

Includes: Supplemental data

Journal Articles

Free hemoglobin: a boost to platelet thrombi

Marc Jacquemin, Kathelijne Peerlinck

Blood (2015) 126 (20): 2262–2263.

https://doi.org/10.1182/blood-2015-09-667642

Published: 2015

Journal Articles

Factor VIII inhibitor: affinity is the clue

Marc Jacquemin, Kathelijne Peerlinck

Blood (2015) 125 (7): 1056–1058.

https://doi.org/10.1182/blood-2014-12-618991

Published: 2015

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool

Tina Shahani, Renaud Lavend'homme, Aernout Luttun, Jean-Marie Saint-Remy, Kathelijne Peerlinck, Marc Jacquemin

Blood (2010) 115 (23): 4902–4909.

https://doi.org/10.1182/blood-2009-07-232546

Published: 2010

Includes: Supplemental data

Journal Articles

Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants

Katrien Devreese, Kathelijne Peerlinck, Marc F. Hoylaerts

Blood (2010) 115 (4): 870–878.

https://doi.org/10.1182/blood-2009-09-244426

Published: 2010

Includes: Supplemental data

Journal Articles

Immune Tolerance Induction by High Doses FVIII in Hemophilia A Patients with Inhibitor Does Not Require Deletion of FVIII-Specific T Cells.

Marc G. Jacquemin, MD, Renaud Lavend’homme, Ms, Thérèse Tinot, Ms, Kathelijne Peerlinck, MD, Jean Marie Saint-Remy, MD, Brigitte Pautard, MD

Blood (2006) 108 (11): 1029.

https://doi.org/10.1182/blood.V108.11.1029.1029

Published: 2006

Journal Articles

FVIII production by human lung microvascular endothelial cells

Marc Jacquemin, Arne Neyrinck, Maria Iris Hermanns, Renaud Lavend'homme, Filip Rega, Jean-Marie Saint-Remy, Kathelijne Peerlinck, Dirk Van Raemdonck, Charles James Kirkpatrick

Blood (2006) 108 (2): 515–517.

https://doi.org/10.1182/blood-2005-11-4571

Published: 2006

Journal Articles

The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure

Kathleen Freson, Rita De Vos, Christine Wittevrongel, Chantal Thys, Johan Defoor, Luc Vanhees, Jos Vermylen, Kathelijne Peerlinck, Chris Van Geet

Blood (2005) 106 (7): 2356–2362.

https://doi.org/10.1182/blood-2005-02-0723

Published: 2005

Includes: Supplemental data

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

Journal Articles

Rupture of T Cell Tolerance to Self Factor VIII in Mild/Moderate Hemophilia A.

Marc G. Jacquemin, MD, PhD, Renaud Lavend’homme, Ms, Benhida Abdellah, Kathelijne Peerlinck, MD, PhD, Jos Vermylen, MD, PhD, Véronique Deneys, MD, PhD, Jean-Marie Saint-Remy, MD, PhD, Cédric Hermans, MD, PhD

Blood (2004) 104 (11): 3076.

https://doi.org/10.1182/blood.V104.11.3076.3076

Published: 2004

Journal Articles

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Roseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, Abdellah Benhida, Jean-Claude Bordet, Claude Negrier, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie Saint-Remy, Marc Jacquemin

Blood (2004) 103 (1): 155–157.

https://doi.org/10.1182/blood-2003-04-1321

Published: 2004

Journal Articles

CD4 + T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A

Marc Jacquemin, Valérie Vantomme, Cécile Buhot, Renaud Lavend'homme, Wivine Burny, Nathalie Demotte, Pascal Chaux, Kathelijne Peerlinck, Jos Vermylen, Bernard Maillere, Pierre van der Bruggen, Jean-Marie Saint-Remy

Blood (2003) 101 (4): 1351–1358.

https://doi.org/10.1182/blood-2002-05-1369

Published: 2003

Journal Articles

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Marc Jacquemin, Renaud Lavend'homme, Abdellah Benhida, Beatrijs Vanzieleghem, Roseline d'Oiron, Jean-Maurice Lavergne, Hans H. Brackmann, Rainer Schwaab, Thierry VandenDriessche, Marinee K. L. Chuah, Marc Hoylaerts, Jean Guy G. Gilles, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie R. Saint-Remy

Blood (2000) 96 (3): 958–965.

https://doi.org/10.1182/blood.V96.3.958

Published: 2000

Journal Articles

Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia

Marguerite Neerman-Arbez, Philippe de Moerloose, Claire Bridel, Ariane Honsberger, Anni Schönbörner, Colette Rossier, Kathelijne Peerlinck, Ségolène Claeyssens, Donna Di Michele, Roseline d'Oiron, Marie Dreyfus, Monique Laubriat-Bianchin, Jacelyne Dieval, Stylianos E. Antonarakis, Michael A. Morris

Blood (2000) 96 (1): 149–152.

https://doi.org/10.1182/blood.V96.1.149

Published: 2000

Journal Articles

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Marc Jacquemin, Abdellah Benhida, Kathelijne Peerlinck, Benoı̂t Desqueper, Luc Vander Elst, Renaud Lavend'homme, Roseline d'Oiron, Rainer Schwaab, Marleen Bakkus, Kris Thielemans, Jean-Guy Gilles, Jos Vermylen, Jean-Marie Saint-Remy

Blood (2000) 95 (1): 156–163.

https://doi.org/10.1182/blood.V95.1.156

Published: 2000

NARROW

Ribosome dysfunction underlies SLFN14-related thrombocytopenia

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders

Free hemoglobin: a boost to platelet thrombi

Factor VIII inhibitor: affinity is the clue

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool

Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants

Immune Tolerance Induction by High Doses FVIII in Hemophilia A Patients with Inhibitor Does Not Require Deletion of FVIII-Specific T Cells.

FVIII production by human lung microvascular endothelial cells

The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Rupture of T Cell Tolerance to Self Factor VIII in Mild/Moderate Hemophilia A.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

CD4 + T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only